Isabella Santi is an Analyst at the AMR Action Fund (AMRAF), where she has helped guide several investments into biotech companies that are developing therapeutics for priority drug-resistant pathogens. Prior to joining AMRAF, she spent nearly two decades in academia, where she developed a deep understanding of bacterial physiology and how pathogen respond to antibiotics. She has authored and co-authored numerous scientific publications. Dr. Santi studied Pharmaceutical Biotechnology at University of Bologna, Italy, and holds a PhD in Molecular and Cellular Biology from the University of Padova.
